Incyte's trial fails to boost Keytruda to treat melanoma
Incyte has scrapped plans for a drug to boost the effectiveness of Merck's Keytruda to treat skin cancer patients after a Phase 3 clinical trial failed.
Source: Health News - UPI.com - Category: Consumer Health News Source Type: news
More News: Cancer | Cancer & Oncology | Clinical Trials | Health | Melanoma | Merck | Skin | Skin Cancer